Oncocross Co., Ltd. (KOSDAQ:382150)

Market Cap	111.59B -6.7%
Revenue (ttm)	370.46M -65.4%
Net Income	-8.93B
EPS	-747.00
Shares Out	12.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	159,505
Average Volume	1,311,839
Open	9,200.00
Previous Close	9,150.00
Day's Range	8,990.00 - 9,210.00
52-Week Range	6,150.00 - 15,470.00
Beta	n/a
RSI	64.18
Earnings Date	May 14, 2026

About Oncocross

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular D...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 382150

Financial Performance

In 2025, Oncocross's revenue was 370.46 million, a decrease of -65.45% compared to the previous year's 1.07 billion. Losses were -8.93 billion, 37.7% more than in 2024.